Gastroenterology News

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.

The AGA reported that it could not issue a recommendation for or against the use of computer-aided detection in colonoscopy due to “very low certainty of evidence” and “the close tradeoff between the desirable and undesirable effects.”

Using etrasimod with opioids or antidepressants did not increase risk for serotonin syndrome-associated adverse events among patients with ulcerative colitis, according to a study published in United European Gastroenterology Journal.

Most pediatric transplant recipients who received live-attenuated viral vaccines after transplant developed protective antibodies that persisted for up to a year after vaccination with no significant safety events, researchers found.

In this episode, guest Austin Chiang, MD, discusses the influence of social media in medicine and how AI continues to change the health care landscape.

The U.S. Multi-Society Task Force on Colorectal Cancer has released updated guidance establishing a “reasonable benchmark” for the quality of bowel preparation prior to a colonoscopy exam.

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference product manufacturer, Janssen Pharmaceuticals, which set timelines for their market entries.

When Ashley Haugen and her husband Jonathan took their daughter to a dermatologist to get a skin tag removed, he pointed to a rash around her mouth and recommended the couple stop using harsh soaps until it clears up.

In this podcast episode, Prateek Sharma, MD, about how program directors can help shepherd GI fellows into clinical research spaces, providing quality exams for upper endoscopy and more.